Acesso livre
Acesso livre

Hematologia Geral

Revisão sistemática | Estabilizadores de HIF (Hypoxia‐Inducible Factor) para a anemia na doença renal crônica.

12 Set, 2022 | 11:25h

Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease – Cochrane Library

Resumo: Are hypoxia-inducible factor stabilisers effective for management of anaemia among people with chronic kidney disease? – Cochrane Library

 


Seguimento de 48 semanas de um estudo randomizado | Pegcetacoplan vs. eculizumabe em pacientes com hemoglobinúria paroxística noturna.

12 Set, 2022 | 11:16h

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link para o resumo – $ para o texto completo)

Estudo original: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine

 

Comentário no Twitter (fio – clique para saber mais)

 


Opinião | Ácido tranexâmico para uma cirurgia mais segura: o momento é agora.

8 Set, 2022 | 14:21h

Tranexamic acid for safer surgery: the time is now – British Journal of Surgery

Conteúdos relacionados:

#ACC22 – RCT: Tranexamic acid reduces the risk of bleeding in patients undergoing noncardiac surgery.

Update on applications and limitations of perioperative tranexamic acid.

RCT | Effect of high- vs. low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery.

Safety of tranexamic acid in hip and knee arthroplasty in high-risk patients – this large observational study did not show an increased risk for venous thromboembolism, myocardial infarction, seizures, ischemic strokes, or transient ischemic attacks, irrespective of patient high-risk status at baseline

M-A: Intravenous tranexamic acid in surgical patients is not associated with increased risk of thromboembolic events and mortality

 


Breve revisão | Tromboprofilaxia na terapia intensiva.

8 Set, 2022 | 14:06h

Thromboprophylaxis in critical care – Intensive Care Medicine

 


Revisão | Uso de transfusão de sangue total no trauma.

8 Set, 2022 | 13:34h

The Use of Whole Blood Transfusion in Trauma – Current Anesthesiology Reports

 


Revisão sistemática | Hidroxiureia para doença falciforme.

6 Set, 2022 | 12:42h

Hydroxyurea (hydroxycarbamide) for sickle cell disease – Cochrane Library

Resumo: Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease – Cochrane Library

 


Revisão | Reações à transfusão sanguínea.

29 Ago, 2022 | 13:38h

Blood Transfusion Reactions—A Comprehensive Review of the Literature including a Swiss Perspective – Journal of Clinical Medicine

 


Estudo de braço único fase 2 | Segurança e eficácia do mitapivate, ativador oral da piruvatequinase, em adultos com alfatalassemia ou betatalassemia não dependente de transfusão.

22 Ago, 2022 | 16:28h

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study – The Lancet (link para o resumo – $ para o texto completo)

Comentário: PK Modulator Shows Promise in Thalassemia — In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients – MedPage Today (necessário cadastro gratuito)

 


Diretriz | Uso de plasma convalescente de COVID-19.

22 Ago, 2022 | 16:08h

Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma – Annals of Internal Medicine

Editorial: The Fast and the Furious: Chasing a Clinical Niche for COVID-19 Convalescent Plasma – Annals of Internal Medicine

Comunicado de imprensa: The AABB releases clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma – American College of Physicians

 


M-A | Eficácia e segurança da anticoagulação com heparina em dose plena em pacientes de COVID-19 internados e não críticos.

16 Ago, 2022 | 13:04h

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials – Journal of Thrombosis and Thrombolysis

Conteúdos relacionados:

Efficacy and safety of intensified versus standard prophylactic anticoagulation therapy in patients with Covid-19: a systematic review and meta-analysis – Open Forum Infectious Diseases

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?

 


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.